- Home
- CHH vs AXSM Comparison
CHH vs AXSM Comparison
Compare CHH & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHH
- AXSM
- Stock Information
- Founded
- CHH 1939
- AXSM 2012
- Country
- CHH United States
- AXSM United States
- Employees
- CHH N/A
- AXSM N/A
- Industry
- CHH Hotels/Resorts
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- CHH Consumer Discretionary
- AXSM Health Care
- Exchange
- CHH Nasdaq
- AXSM Nasdaq
- Market Cap
- CHH 4.9B
- AXSM 5.9B
- IPO Year
- CHH 1997
- AXSM 2015
- Fundamental
- Price
- CHH $101.34
- AXSM $118.28
- Analyst Decision
- CHH Hold
- AXSM Strong Buy
- Analyst Count
- CHH 15
- AXSM 19
- Target Price
- CHH $133.87
- AXSM $174.26
- AVG Volume (30 Days)
- CHH 471.2K
- AXSM 472.6K
- Earning Date
- CHH 11-05-2025
- AXSM 11-03-2025
- Dividend Yield
- CHH 1.13%
- AXSM N/A
- EPS Growth
- CHH 34.90
- AXSM N/A
- EPS
- CHH 6.50
- AXSM N/A
- Revenue
- CHH $797,866,000.00
- AXSM $495,033,000.00
- Revenue This Year
- CHH $100.21
- AXSM $63.62
- Revenue Next Year
- CHH $3.79
- AXSM $55.72
- P/E Ratio
- CHH $15.60
- AXSM N/A
- Revenue Growth
- CHH N/A
- AXSM 69.83
- 52 Week Low
- CHH $100.98
- AXSM $75.56
- 52 Week High
- CHH $157.86
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- CHH 25.85
- AXSM 52.00
- Support Level
- CHH $104.81
- AXSM $117.60
- Resistance Level
- CHH $108.61
- AXSM $122.14
- Average True Range (ATR)
- CHH 2.33
- AXSM 3.15
- MACD
- CHH -0.33
- AXSM -0.28
- Stochastic Oscillator
- CHH 1.81
- AXSM 36.43
About CHH Choice Hotels International Inc.
As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.